Details for Patent: 7,807,708

Which drugs does patent 7,807,708 protect, and when does it expire?

Patent 7,807,708 protects AKLIEF and is included in one NDA.

This patent has twenty-seven patent family members in twenty-three countries.

Summary for Patent: 7,807,708

Title:	Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
Abstract:	Novel ligand compounds having the general formula (I): ##STR00001## and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.
Inventor(s):	Biadatti; Thibaud (Opio, FR), Dumais; Laurence (Le Rouret, FR), Soulet; Catherine (Antibes, FR), Talano; Sandrine (Vence, FR), Daver; Sebastien (Antibes, FR)
Assignee:	Galderma Research & Development (Biot, FR)
Application Number:	11/819,068
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 7,807,708

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	AKLIEF	trifarotene	CREAM;TOPICAL	211527-001	Oct 4, 2019		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 7,807,708

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	04 13848	Dec 23, 2004
	PCT/EP2005/014217	Dec 21, 2005

International Family Members for US Patent 7,807,708

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	055297
Austria	E542791
Australia	2005318292